Matches in SemOpenAlex for { <https://semopenalex.org/work/W4299321618> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4299321618 endingPage "6" @default.
- W4299321618 startingPage "54" @default.
- W4299321618 abstract "(1) Treatment of uncomplicated malaria acquired in areas of chloroquine resistance is based on oral drugs chosen according to local resistance patterns. The atovaquone + proguanil combination is often the first choice for travelers because of its tolerability and convenience. (2) For the treatment of uncomplicated malaria, artemisinin derivatives, extracted from a Chinese plant, have a short-lived action and should not therefore be used as monotherapy. (3) Only one combination of this type, artemether plus lumefantrine (an antimalarial related to halofantrine), is marketed in France for the treatment of uncomplicated malaria. (4) In African trials, the efficacy of the artemether + lumefantrine combination, taken in 6 doses over 3 days, was fairly consistent and similar (or even superior) to that of the amodiaquine + sulfadoxine + pyrimethamine combination in three trials. It was more effective than the quinine + doxycycline combination in a region of Brazil where strains with diminished sensitivity to quinine circulate. (5) Artemether has the adverse effects of all artemisinin derivatives, especially gastrointestinal and neurological disorders. Lumefantrine, a drug related to halofantrine, prolongs the QT interval (albeit less than halofantrine), and this sometimes warrants ECG monitoring and blood potassium assays, especially in patients who have hepatic or renal failure or who are taking other drugs that affect the QT interval. (6) The absorption of lumefantrine is dependent on the presence of food in the stomach, which can be difficult as loss of appetite and nausea are frequent during malaria attacks. Intake of about 1.5 g of fat seems sufficient for satisfactory absorption. The artemether + lumefantrine combination is effective in case of resistance to other antimalarials. It is an alternative to the atovaquone + proguanil combination for travelers." @default.
- W4299321618 created "2022-10-02" @default.
- W4299321618 date "2008-04-01" @default.
- W4299321618 modified "2023-10-18" @default.
- W4299321618 title "Artemether + lumefantrine: new drug. An alternative to atovaquone + proguanil." @default.
- W4299321618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18516806" @default.
- W4299321618 hasPublicationYear "2008" @default.
- W4299321618 type Work @default.
- W4299321618 citedByCount "0" @default.
- W4299321618 crossrefType "journal-article" @default.
- W4299321618 hasConcept C126322002 @default.
- W4299321618 hasConcept C203014093 @default.
- W4299321618 hasConcept C2776120307 @default.
- W4299321618 hasConcept C2776992834 @default.
- W4299321618 hasConcept C2776999253 @default.
- W4299321618 hasConcept C2777199930 @default.
- W4299321618 hasConcept C2777498558 @default.
- W4299321618 hasConcept C2778048844 @default.
- W4299321618 hasConcept C2778118209 @default.
- W4299321618 hasConcept C2778371730 @default.
- W4299321618 hasConcept C2778629330 @default.
- W4299321618 hasConcept C2779124865 @default.
- W4299321618 hasConcept C2779636613 @default.
- W4299321618 hasConcept C2780780316 @default.
- W4299321618 hasConcept C2781160685 @default.
- W4299321618 hasConcept C71924100 @default.
- W4299321618 hasConcept C98274493 @default.
- W4299321618 hasConceptScore W4299321618C126322002 @default.
- W4299321618 hasConceptScore W4299321618C203014093 @default.
- W4299321618 hasConceptScore W4299321618C2776120307 @default.
- W4299321618 hasConceptScore W4299321618C2776992834 @default.
- W4299321618 hasConceptScore W4299321618C2776999253 @default.
- W4299321618 hasConceptScore W4299321618C2777199930 @default.
- W4299321618 hasConceptScore W4299321618C2777498558 @default.
- W4299321618 hasConceptScore W4299321618C2778048844 @default.
- W4299321618 hasConceptScore W4299321618C2778118209 @default.
- W4299321618 hasConceptScore W4299321618C2778371730 @default.
- W4299321618 hasConceptScore W4299321618C2778629330 @default.
- W4299321618 hasConceptScore W4299321618C2779124865 @default.
- W4299321618 hasConceptScore W4299321618C2779636613 @default.
- W4299321618 hasConceptScore W4299321618C2780780316 @default.
- W4299321618 hasConceptScore W4299321618C2781160685 @default.
- W4299321618 hasConceptScore W4299321618C71924100 @default.
- W4299321618 hasConceptScore W4299321618C98274493 @default.
- W4299321618 hasIssue "94" @default.
- W4299321618 hasLocation W42993216181 @default.
- W4299321618 hasOpenAccess W4299321618 @default.
- W4299321618 hasPrimaryLocation W42993216181 @default.
- W4299321618 hasRelatedWork W1561073763 @default.
- W4299321618 hasRelatedWork W1571339142 @default.
- W4299321618 hasRelatedWork W2020097124 @default.
- W4299321618 hasRelatedWork W2110269548 @default.
- W4299321618 hasRelatedWork W2120453248 @default.
- W4299321618 hasRelatedWork W2126585535 @default.
- W4299321618 hasRelatedWork W2152312680 @default.
- W4299321618 hasRelatedWork W2155737651 @default.
- W4299321618 hasRelatedWork W2781676200 @default.
- W4299321618 hasRelatedWork W89733597 @default.
- W4299321618 hasVolume "17" @default.
- W4299321618 isParatext "false" @default.
- W4299321618 isRetracted "false" @default.
- W4299321618 workType "article" @default.